Patients who develop cytokine release syndrome after chimeric antigen receptor T-cell therapy for autoimmune disease ...
A small longitudinal study of 12 transplant recipients found that two-dimensional B-cell receptor analysis revealed ...
Laboratory experiments with human tonsil-derived fibroblasts show that senescent lymphoid stromal cells suppress B cell ...
The influx of novel therapies is expanding treatment options for patients with cancer, but distance, infrastructure, and ...
The case study demonstrates a durable complete response in a heavily pretreated DLBCL patient after a single administration ...
Durable Complete Response Achieved with Single Administration of Iopofosine I 131 Provides Additional Clinical Support for the Differentiated ...
In the Phase 3 MagnetisMM-32 trial, ELREXFIO demonstrated a clinically meaningful and statistically significant benefit for ...
Company halting further development of AlloNK® (AB-101), including the planned phase 3 pivotal trialUpdated deep B cell depletion and clinical response data is consistent with previously reported ...
Artiva Biotherapeutics (NASDAQ:ARTV) shares fell 32% Tuesday after the company announced it is halting further development of AlloNK (AB-101), including a planned phase 3 pivotal trial.
For patients with autoimmune disease, higher baseline B-cell counts and systemic inflammation are associated with development ...
Six-year-old Philip Warstler is fighting against Pre B-Cell Acute Lymphoblastic Leukemia.
Fintel on MSN
Climb Bio, Inc. Announces Initial PrisMN Phase 2 Data for Budoprutug in Primary Membranous Nephropathy
Climb Bio, Inc. announced initial PrisMN Phase 2 data for budoprutug, its anti-CD19 monoclonal antibody, in primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results